COMMUNIQUÉS West-GlobeNewswire

Commure Autonomous Coding Achieves Epic Toolbox Designation for Fully Autonomous Coding
20/10/2026
Commure now holds Epic Toolbox designations across both Ambient AI and Autonomous Coding, connecting documentation and coding inside Epic. MOUNTAIN VIEW, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Commure, a leading AI- [...]
The Trigeminal Neuralgia Institute Launches to Drive Research and Bring Specialist Care to Patients
20/10/2026
20 October 2026 : A new UK charity has launched, dedicated to improving our understanding of trigeminal neuralgia (TN) and ensuring that every patient, wherever they live, has access to a diagnosis, followed by care [...]
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
20/10/2026
Access the Moleculin CEO Corner here HOUSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has released the next segment on its CEO [...]
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
20/10/2026
PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before [...]
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
20/10/2026
Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days Intestinal exposure and tissue analyses strengthen [...]
Route 92 Medical Announces $100 Million Corporate Debt Facility
20/10/2026
Financing Strengthens Balance Sheet and Supports Continued Product Innovation and Commercial Growth WEST JORDAN, Utah, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a medical technology company dedicated to [...]
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
20/10/2026
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and [...]
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
20/10/2026
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer ( [...]
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
20/10/2026
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for [...]
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
20/10/2026
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney [...]
InnovAge to Announce Fiscal First Quarter 2027 Financial Results and Host Conference Call Tuesday, November 3, 2026
20/10/2026
DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
20/10/2026
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
20/10/2026
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct. 20, 2026 (GLOBE [...]
Biomolecular Holdings Announces Issuance of Foundational Patent for Revolutionary Dimeric Fusion Protein Technology
20/10/2026
BURLINGAME, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Biomolecular Holdings LLC, a privately held biotechnology company advancing next-generation antibody architectures, today announced that the United States Patent and [...]
Alignment Health Plan Recognized Among U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage
20/10/2026
Alignment earns “Best” rating in Arizona, California, Nevada, North Carolina and Texas for the second consecutive year, reflecting strong performance in care quality, prevention and satisfaction ORANGE, Calif., Oct. 20 [...]
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
20/10/2026
ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release [...]
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
20/10/2026
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced that the US Food and Drug Administration ( [...]
The Consortium for Top-Down Proteomics is now The Proteoform Alliance, with the Expanded Mission to Unlock the Full Potential of Proteoform Biology
20/10/2026
Proteoforms are the primary effectors of biological function, and uniting the various technologies, applications, and institutions in one organization will greatly increase our knowledge and capabilities for proteoform- [...]
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
20/10/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on [...]

Pages